BIRMINGHAM, Ala.--(BUSINESS WIRE)--Atherotech, Inc., a pioneer in cardiodiagnostic cholesterol testing technology renowned for its VAP Cholesterol Test, today announced the additions of Laura G. King and Kenneth M. Roe as independent members to its board of directors. Most recently, King served as President and CEO of the $1.2 billion GE Healthcare Interventional Cardiology Business. Roe, currently retired, last served as Regional Vice President and Operations Leader for Quest Diagnostics Incorporated, where he oversaw lab operations exceeding $1 billion in annual revenue.
